Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Trastuzumab Stories

2012-05-16 02:30:09

MOUNTAIN VIEW, Calif., May 16, 2012 /PRNewswire/ -- Although there are approximately 27 drugs on the market indicated for the treatment of breast cancer, there is currently an unmet need to treat patients. Consequently, there are abounding opportunities for pharmaceutical manufacturers, as breast cancer is the second most common cancer among women. There are currently 55 breast cancer therapeutic drugs in the developmental phase in the U.S., with additional drugs expected to...

2012-05-15 12:42:01

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently no reliable method for early detection or therapeutic intervention. Pancreatic ductal adenocarcinoma, or PDAC, is the fourth-leading cause of cancer-related death. Newly diagnosed patients have a median survival of less than one year, and a 5-year survival rate of...

2012-05-11 14:25:57

Chemotherapy is a major first line defense against breast cancer. However a patient's response is often variable and unpredictable. A study published in BioMed Central's open access journal BMC Medical Genomics shows that 'gene expression signatures' for TOP2A and β-tubulin can be used to predict the outcome of chemotherapy. The goal of personalized medicine in cancer treatment is to target therapy to the characteristics of the individual tumor. For example Herceptin treatment is of...

2012-04-25 02:30:59

NEWCASTLE UPON TYNE, England, April 25, 2012 /PRNewswire/ -- Leica Biosystems, a division of Leica Microsystems, announced that it has received Pre-Market Approval from the U.S. Food and Drug Administration for the Leica Bond Oracle HER2 IHC System (Product Code TA9147) with the Leica BOND-MAX, establishing their commitment to developing quality companion diagnostic products. The Leica Bond Oracle HER2 IHC System is a complete solution of ready-to-use reagents, HER2 control...

2012-04-18 10:25:01

Combination of antibody fragment and packaging peptide addresses siRNAs to breast tumor cells BOSTON, Mass., April 18, 2012 /PRNewswire-USNewswire/ -- Researchers in the Program in Cellular and Molecular Medicine at Boston Children's Hospital and the Immune Disease Institute (PCMM/IDI) have developed a molecular delivery platform that overcomes one of the biggest obstacles to using RNA-based gene silencing technologies to treat cancer: Making sure the treatment gets to the right...

2012-04-18 12:45:43

Adding trastuzumab (trade name Herceptin) to the treatment offered to women who have HER2-positive breast cancer, significantly increases the chance of life being prolonged, and reduces the chance of tumours reappearing once therapy stops. This is important, because about one-fifth of women who develop early breast cancer have HER2-positive tumours that, if untreated, are associated with a worse outlook than HER2-negative tumours. At the same time, however, women given trastuzumab have a...

2012-04-09 02:24:07

WALTHAM, Mass., April 9, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announced that investigators at The University of Texas MD Anderson Cancer Center Department of Breast Medical Oncology have initiated a phase 1/2 study combining Syndax's lead product entinostat with lapatinib ditosylate (Tykerb) in patients with locally recurrent or distant relapsed metastatic breast cancer previously treated with trastuzumab (Herceptin®). The study...

2012-04-04 21:16:41

An international team of scientists, including four at Simon Fraser University, has made a discovery that will change the way the most deadly form of breast cancer is treated. The journal Nature has just published the team's findings online in the paper The clonal and mutational evolution spectrum of primary triple negative breast cancers. The study is the largest genetic analysis of what were thought to be triple negative breast cancer tumors. The 59 scientists involved in this...

2012-03-29 23:27:19

A new study has identified a key mechanism that causes breast cancer to spread. The research, published by Cell Press on March 30th in the journal Molecular Cell, enhances our knowledge about the signals that drive cancer metastasis and identifies new therapeutic targets for a lethal form of invasive breast cancer that is notoriously resistant to treatment. Amplification of the gene for ErbB2 has been linked with aggressive forms of breast cancer and is associated with a poor outcome....

2012-03-15 23:37:11

Antibodies, once touted as the "magic bullets" of cancer care, are now fulfilling that promise and more advances are on the way, say cancer researchers at the Georgetown Lombardi Comprehensive Cancer Center In a review article posted online March 16 in Cell, the researchers say that refinements and modifications of monoclonal antibody drugs -- several of which have already revolutionized the care of breast and colon cancer --are now being tested in most tumor types. These modifications...